Dignity Health | Comprehensive Blood and Cancer Center
Status and phase
Conditions
Treatments
About
This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have completed both neoadjuvant and postoperative adjuvant standard of care therapy. Treatment consists of 6 intradermal injections, Primary Immunization Series (PIS), over the first 6 months of treatment and 5 booster intradermal injections spaced 6 months apart. A third open-label arm will explore GLSI-100 immunotherapy in non-HLA-A*02 positive and HER2/neu positive subjects.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
598 participants in 3 patient groups, including a placebo group
Loading...
Central trial contact
Jaye L Thompson, Ph.D.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal